^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) + PLX51107 (BET inhibitor, MYC inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
...taking 120 mg daily of PLX51107 and 60 mg daily of quizartinib), the combination induced synergistic cytotoxicity in a series of 10 different FLT3-ITD AML patient blast samples co-cultured with bone marrow stroma (Figure 3).
DOI:
10.1182/blood-2019-124030
